AstraZeneca Plc - Company Snapshot & SWOT Analysis

June 2019 | 46 pages | ID: A76DC54A1DFEN
NAVADHI Market Research Pvt Ltd

Abstracts

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory.

AstraZeneca reported revenue of USD 22.090 billion for the FY 2018 which saw an increase of 1.67% compared to FY 2017. This revenue is expected to increase by 6% and reach USD 23.415 billion by FY 2019. AstraZeneca revenue decreased at a CAGR of 2.99% during FY 2013 to FY 2018.

AstraZeneca registered the highest revenue from Cardiovascular, Renal, and Metabolism therapy area at USD 6.710 billion which accounted for 31.88% of its total sales in FY 2018. In FY 2018, AstraZeneca registered the highest revenue from the United States market at USD 7.24 billion which accounted for 32.78% of its total sales in FY 2018. This was followed by China with revenue of USD 3.778 billion accounting for 17.10% of total FY 2018 sales and United Kingdom with revenue of USD 2.39 billion and accounting for 10.82% of total FY 2018 sales.

Scope of the AstraZeneca PLC - Company Snapshot & SWOT Analysis Report

• This report provides detailed information about AstraZeneca PLC including value chain analysis, financial performance, business strategy, and SWOT analysis.
• The report identifies the growth drivers and inhibitors for the global pharmaceutical market.
• This report provides information about current and future trends for the global pharmaceutical market.

Contents

1. EXECUTIVE SUMMARY

Scope of the AstraZeneca PLC - Company Snapshot & SWOT Analysis Report
Research Methodology

2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET

3. COMPANY PROFILE

3.1 AstraZeneca PLC
  3.1.1 Company Profile
  3.1.2 AstraZeneca PLC in Global Pharmaceuticals Manufacturing Value Chain
  3.1.3 AstraZeneca PLC: Financial Performance
    3.1.3.1 AstraZeneca PLC: Overall Revenue FY 2013-FY 2019 (in USD billion)
    3.1.3.2 AstraZeneca PLC: Geography-Wise Revenue FY 2018 (in USD billion)
    3.1.3.3 AstraZeneca PLC: Therapy Area-Wise Revenue FY 2018 (in USD billion)
  3.1.4 AstraZeneca PLC: Business Strategy
    3.1.4.1 Product Level Strategy
  3.1.5 SWOT Analysis of AstraZeneca Plc
Strengths
Weaknesses
Opportunities
Threats

4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET

Orphan Drugs
Biologics and Biosimilars
Current Trends

1. INCREASING SEVERITY OF DRUG PRICE CONTROLS

2. GREATER FOCUS ON RARE DISEASES/ORPHAN DRUGS

3. INCREASING DEVELOPMENT OF NUCLEIC ACIDS AS THERAPEUTICS

4. INCREASING FOCUS ON CELL THERAPY

5. IMPLANTABLES (BIOELECTRONICS) AND ELECTROCEUTICALS ARE EXPECTED TO BECOME MAINSTREAM

6. USE OF 3D PRINTING TO REDUCE COST AND IMPROVE PRODUCTION EFFICIENCY OF BIOLOGICS

7. INCREASING USE OF BIG DATA AND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY

Notes
Company Information

List Of Exhibits

LIST OF EXHIBITS

Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key Information of AstraZeneca PLC
Exhibit 3.2 Contact Information of AstraZeneca PLC
Exhibit 3.3 AstraZeneca PLC in Pharmaceuticals Manufacturing Value Chain
Exhibit 3.4 Revenue of AstraZeneca PLC FY 2013-FY 2019 (in USD billion)
Exhibit 3.5 Revenue Growth of AstraZeneca PLC FY 2014-FY 2019 (in %)
Exhibit 3.6 Geography-Wise Revenue of AstraZeneca PLC in FY 2018 (in USD billion)
Exhibit 3.7 United States Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 3.8 United States Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 3.9 China Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 3.10 China Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 3.11 United Kingdom Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 3.12 United Kingdom Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 3.13 France Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 3.14 France Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 3.15 Germany Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 3.16 Germany Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 3.17 Italy Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 3.18 Italy Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 3.19 Spain Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 3.20 Spain Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 3.21 Sweden Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 3.22 Sweden Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 3.23 Rest of Europe Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 3.24 Rest of Europe Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 3.25 Rest of Europe Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 3.26 Canada Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 3.27 Rest of Americas Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 3.28 Rest of Americas Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 3.29 Australia Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 3.30 Australia Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 3.31 Japan Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 3.32 Japan Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 3.33 Rest of Asia, Africa & Australia Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
Exhibit 3.34 Rest of Asia, Africa & Australia Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
Exhibit 3.35 Therapy Area-Wise Revenue of AstraZeneca PLC in FY 2018 (in USD billion)
Exhibit 3.36 Therapy and Geography Area-Wise Revenue of AstraZeneca PLC FY 2018 (in USD billion)
Exhibit 3.37 SWOT Analysis of AstraZeneca PLC